Securities code: 300497 securities abbreviation: Jiangxi Fushine Pharmaceutical Co.Ltd(300497) Announcement No.: 2022-005 Jiangxi Fushine Pharmaceutical Co.Ltd(300497)
Announcement on changing the business scope and amending the articles of Association
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) (hereinafter referred to as “the company”) the company held the 27th meeting of the third board of directors on January 6, 2022, and deliberated and adopted the regulations on changing business scope and revising
<公司章程>
According to the actual business situation of the company, it is necessary to adjust the business scope of the company and revise the corresponding provisions of the articles of association. The details are as follows:
1、 Changes in business scope
Original business scope: manufacturing and sales of API (operated with drug production license); Production and sales: sulbactam acid, sultamicillin tosilate, sultamicillin base, sulbactam pivoxil, tazobactam, meropenem, imipenem, piperacillin, AA6, sulbactam sodium, triethylamine, diethylamine, n-butanol, dichloromethane, tetrahydrofuran, ethanol, ethyl acetate, acetone, methanol, N, N-dimethylformamide, toluene Bromine (operate according to the approved scope of work safety license, which is valid until August 30, 2021); Manufacturing and sales of chemical raw materials (excluding dangerous chemicals); Operate import and export business. (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments)***
Business scope after change: drug manufacturing and sales (operating with drug production license); Production and sales: sulbactam acid, tosilate, sultamicillin, sultamicillin base, sulbactam pivoxil, tazobactam, meropenem, imipenem, piperacillin, AA6, sulbactam sodium; Sales: triethylamine, diethylamine, n-butanol, dichloromethane, tetrahydrofuran, ethanol, ethyl acetate, acetone, methanol, N, N-dimethylformamide, toluene and bromine (according to safety requirements)
The business scope approved by the production license is valid until August 30, 2024); Operate import and export business. (for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments)***
2、 Amendments to the articles of Association
Before and after revision
Article 13 business scope of the company: approved article 13 business scope of the company: drug manufacturing and marketing items: manufacturing and marketing of API (manufacturing and marketing of drugs (operating with drug production license); Production license operation), general business items: production and sales of chemical raw materials: Manufacture and sales of sulbactam acid, tosilate, sultamicillin and sulbactam (excluding dangerous chemicals); Production and marketing of tamoxilline, sulbactam pivoxil, tazobactam, American sales: sulbactam acid, tosilate, sulbactam, sulbactam openem, imipenem, piperacillin, AA6, Sulin alkali, sulbactam pivoxil, tazobactam, meropenem and Batam sodium; Sales: triethylamine, diethylamine, n-butyl imipenem, piperacillin, AA6, sulbactam sodium, alcohol, dichloromethane, tetrahydrofuran, ethanol, ethyltriethylamine acetate, diethylamine, n-butanol, dichloromethane, tetraester, acetone, methanol, N, N-dimethylformamide, hydrofuran, ethanol, ethyl acetate, acetone, methanol, toluene Bromine (n, N-dimethylformamide, toluene and bromine approved according to the work safety license (the validity period of the license is from August 30, 2024 to August 30, 2021, based on the work safety license); Operate import and export business. (licensed operation subject to approval according to law); Operate import and export business (subject to the scope of the living right certificate for import and export projects that can be carried out only after being approved by relevant departments). (moving)
Other provisions of the articles of association remain unchanged.
This change needs to be submitted to the general meeting of shareholders of the company for deliberation and approved by Jingdezhen market supervision and Administration Bureau. The board of directors submits to the general meeting of shareholders and authorizes the board of directors to go through relevant industrial and commercial change registration procedures. The business scope after change shall finally be subject to the approval and registration of Jingdezhen market supervision and Administration Bureau.
It is hereby announced.
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) board of directors
January 6, 2022
